Advertisement
Advertisement
U.S. Markets close in 2 hrs 2 mins
Advertisement
Advertisement
Advertisement
Advertisement

Benitec Biopharma Inc. (BNTC)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
3.6301-0.0499 (-1.36%)
As of 1:27PM EDT. Market open.
Advertisement
Full screen
Loading interactive chart...
  • PR Newswire

    Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results

    Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today provided an operational update and announced the financial results for its fiscal year ended June 30, 2021. The Company has filed its annual report on Form 10-K for the year ended June 30, 2021, with the U.S. Securities and Exchange Commission.

  • PR Newswire

    Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference

    Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The relevant details are outlined below:

  • PR Newswire

    Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022

    Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today provided an overview of the key elements of the BB-301 Phase 1b/2a clinical trial design. The clinical trial is planned for 2022.

Advertisement
Advertisement